Homepage Inria website
OPIS - 2019

Overall Objectives
New Software and Platforms
New Results
Bilateral Contracts and Grants with Industry

Section: Application Domains

Imaging radiomics and genes to assess immunotherapy

Participants: Samy Ammari, Enzo Batistella, Emilie Chouzenoux, Théo Estienne, Marvin Lerousseau, Hugues Talbot, Roger Sun, Maria Vakalopoulou (in collaboration with Corinne Balleyguier, Caroline Caramella, Éric Deutsch, Nathalie Lassau, Institut de Cancérologie Gustave Roussy, Nikos Paragios, Therapanacea)

Because responses of cancer patients to immunotherapy can vary considerably, innovative predictors of response to treatment are urgently needed to improve patients outcomes.

We have aimed to develop and independently validate a radiomics-based biomarkers of tumour-infiltrating CD8 cells in patients included in phase 1 trials of anti-programmed cell death protein (PD)-1 or anti-programmed cell death ligand 1 (PD-L1) mono-therapy. We also aimed to evaluate the association between the biomarker, tumour immune phenotype and clinical outcomes of these patients.

Concurrently, we have evaluated various ways of estimating patient response to treatment based on well-established radiomics such as estimated tumour count and volumes. Among published metrics, we have select those that shown good predictive power and proposed a new one, which is particularly effective for patient with a poor response [63].

Furthermore, we have developed and validated a novel imaging-based decision-making algorithm for use by the clinician that helps differentiate pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy [21].

These works are in collaboration with the Institut de Cancérologie Gustave Roussy Paris.